ClinicalTrials.gg

Program

DR10624

A development code. Also written as “DR10624 Injection”, “DR10624 for injection” and “DR10624 Subcutaneous Injection”.

Its studies are mostly in Hypertriglyceridemia · Obesity, Metabolically Benign · Non-alcoholic Fatty Liver Disease, led by Huadong Medicine.

Furthest: phase 3, since Jun 24, 20266 company-led studies, 4 open or runningNext primary completion: Apr 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine64 open or runningphase 3since Jun 24, 2026Mar 25, 2022Apr 2028phase 2 · NCT07848880

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2022First study: phase 1 study in Obesity, Metabolically BenignFirst studyNCT05378893 · 153 enrolled · New Zealand
  2. Jul 30, 2024Phase 2 study in HypertriglyceridemiaNCT06555640 · 79 enrolled · China
  3. Apr 24, 2025Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07024212 · 110 enrolled · China, Hong Kong
  4. Jun 24, 2026Phase 3 study in HypertriglyceridemiaPhase 3 reachedNCT07680829 · 378 planned · China
  5. Jul 1, 2026Phase 3 study in HypertriglyceridemiaNCT07693777 · 480 planned · China
  6. Sep 24, 2026Phase 2 study in HypertriglyceridemiaNCT07848880 · 315 planned · China

Ahead

  1. Apr 2028Primary completion: phase 2 study in HypertriglyceridemiaNCT07848880
  2. Feb 14, 2029Primary completion: phase 3 study in HypertriglyceridemiaNCT07693777
  3. Jun 2030Primary completion: phase 3 study in HypertriglyceridemiaNCT07680829

TargetBeta

GCGR →GLP1R →read by rule
“DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
efinopegdutideJohnson & Johnsonphase 215
AZD9550AstraZenecaphase 27
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07848880Hypertriglyceridemia · China2Not yet recruitingApr 2028315
NCT07693777Hypertriglyceridemia · China3Not yet recruitingFeb 14, 2029480
NCT07680829Hypertriglyceridemia · China3Not yet recruitingJun 2030378
NCT07024212Non-alcoholic Fatty Liver Disease · China, Hong Kong2Active, not recruitingJun 18, 2026110
NCT06555640Hypertriglyceridemia · China2CompletedJun 30, 202579
NCT05378893Obesity, Metabolically Benign · New Zealand1CompletedOct 10, 2024153

How it is read

Names in the registry

  • “DR10624 Injection”, 4 entries
  • “DR10624 for injection”, 1 entry
  • “DR10624 Subcutaneous Injection”, 1 entry

Codes read as this program: DR10624.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.